DUBLIN--(BUSINESS WIRE)--The "Report Package: Immunotherapy with Oncolytic Viruses and mRNA Vaccines & Therapeutics" report has been added to Research and Markets' offering.
mRNA is a rather versatile therapeutic modality and offers a range of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein.
This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.
It is increasingly recognized that oncolytic viruses not only are able to directly lyse cancer cells, but they also free" tumor specific neoantigens, indirectly acting as a cancer vaccine. The so far modest efficacy of oncolytic viruses still can be improved when combined with immune checkpoint inhibitors. This lead to an increased partnering interest of the major immuno-oncology (I-O) players, but also of investors who view oncolytic viruses as a must be for I-O combination regimens.
Optimization of oncolytic viruses is ongoing and new constructs intend to solve some of the open problems regarding the way of administration (intratumoral vs systemic), higher cancer cell specific replication capacity, and longer persistence in vivo.
The original reports were published in January and June 2017, respectively:
- The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities
- mRNA Vaccines & Therapeutics 2017: an industry analysis of technologies, pipelines, stakeholders and deals
Key Topics Covered:
mRNA Vaccines & Therapeutics 2017: an industry analysis of technologies, pipelines, stakeholders and deals
1 Executive Summary
2 Introduction & Overview
3 Profiles of mRNA-based Vaccines & Therapeutics
4 Pipeline Analysis
5 Profiles of Selected mRNA & Delivery Technologies
6 Technology Analysis
7 Company Profiles
8 Stakeholder Analysis
9 mRNA Manufacturing
10 Financial Perspective on mRNA
11 Outlook
12 References
The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities
1 Executive Summary
2 Introduction & Overview
3 Selection, Design & Construction of Oncolytic Viruses
4 Profiles of Oncolytic Viruses
5 Analysis of Oncolytic Virus Pipeline
6 Company Profiles
7 Stakeholder Analysis
8 Financing & Partnering
9 Trends & Opportunities
10 References
Companies Mentioned
- Acuitas Therapeutics
- Alexion Pharmaceuticals
- AstraZeneca
- Bayer
- Benevir Biopharm
- BioNTech
- Boehringer Ingelheim
- CureVac
- DNAtrix
- Daiichi Sankyo
- MaxCyte
- Medigen Biotechnology
- Merck
- Moderna Therapeutics
- Multivir
- Otsuka Pharmaceutical Co
- Pfizer
- PhaseRx
- Precision NanoSystems
- Profectus Biosciences
- PsiOxus
- RaNa Therapeutics
- Regeneron Pharmaceuticals
- Replimune
- Roche
- Sangamo Therapeutics
- Sanofi
- Shanghai Sunway Biotech
- Siemens
- Silence Therapeutics
- Vertex Pharmaceuticals
- Western Oncolytics
- ZIOPHARM Oncology
- eTheRNA immunotherapies
For more information about this report visit https://www.researchandmarkets.com/research/p3bzlh/report_package
